Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:47:39.181Z.
Calculation as of: 2026-10-06T18:47:39.181Z.
Quote observation: 2026-10-06T18:44:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$104.18M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.45M
EBITDA Yield
N/A
TTM Avg
3.06%
3Y Avg
3.06%
5Y Avg
3.06%
Market Cap
$105.20M
EBITDA Yield
204.26%
TTM Avg
162.58%
3Y Avg
142.94%
5Y Avg
38.81%
Market Cap
$103.43M
EBITDA Yield
N/A
TTM Avg
6.77%
3Y Avg
6.77%
5Y Avg
6.77%
Market Cap
$106.61M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $104.18M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.45M | N/A | 3.06% | 3.06% | 3.06% |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | 204.26% | 162.58% | 142.94% | 38.81% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.43M | N/A | 6.77% | 6.77% | 6.77% |
| Vivani Medical, Inc. (VANI)vs › | $108.66M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $102.63M | 3.83% | 2.60% | 2.68% | 2.72% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.61M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.46M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $107.06M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.05M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
